top of page

Four wholly owned drugs will be Phase 1b/Phase 2 in 2025

DRAGONFLY's mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes

 

We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond.

In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET® and CYTOKINE platforms have generated 11 Drug Candidates that have been handed off to partners.

Engaging the Immune
System to Fight Disease

icon1.png

Milestone Payment Following Dosing of First Patient

icon4_edited.png

Dragonfly Announces Clinical Collaboration to Evaluate DF9001

icon2.png

Susan Altschuller Joins as CFO of Dragonfly 

Dragonfly 
Latest News

Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC

The company today announced the company will deliver poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Conference,  highlighting preclinical data supporting two clinical-stage assets, DF6215, its engineered IL-2 cytokine, and DF9001, its EGFR-targeting TriNKET, for the treatment of advanced solid tumors.

Our Collaborations

DRAGONFLY is a distinctively effective pharma partner.

Dragonfly rapidly develops drugs with our pharma partners in expanding fields from autoimmune disease and oncology, to neuro-inflammation, neuromuscular disease, virology, and beyond.

bms_logo_rgb_pos-with-border_edited_edit
Abbvie-Logo-2_edited_edited.png
303_main_edited_edited.png
MERCK-logo_edited.png
dfly-graphic-v3_2_2x-80.jpg

Our Platform

TriNKET®
CYTOKINE

Two Proprietary Platforms

DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs in autoimmune disease and oncology, built on two unique platforms: first-in-class tri-specific immune engagers (“TriNKET®s”) and best-in-class CYTOKINEs – each with lead drugs in the clinic with encouraging results. 

Growing the
Pipeline for Patients

In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 30+ TriNKETs® and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.

IL2.png
IL12.png

DRAGONFLY's pipeline is rapidly growing in a number of
therapeutic areas of critical patient need.

molecule_edited.png
bottom of page